New York, New York--(Newsfile Corp. - January 28, 2026) - Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Wealthfront Corporation (NASDAQ: WLTH) for potential violations of the federal securities laws. If you invested in Wealthfront, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/wealthfront-corporation-class-action.Why is Wealthfront Being Investigated for Violations of the Federal Securities Laws? Wealthfront is an onli ...

Core Viewpoint - Block & Leviton is investigating Carvana Co. for potential securities law violations following a report alleging that the company's profitability is based on undisclosed related-party transactions [1][2]. Group 1: Company Performance and Allegations - Carvana's shares fell over 20% on January 28, 2026, after a report from Gotham City Research claimed that the company relies on undisclosed transactions with DriveTime and Bridgecrest to report profitability [2]. - The report alleges that DriveTime incurred over $1 billion in cash losses while leveraging up to 20x to 40x EBITDA to support Carvana's earnings [2]. - It is also claimed that Bridgecrest marked down billions in loans while Carvana recognized gains from loan sales [2]. Group 2: Legal Actions and Investor Information - Block & Leviton is investigating whether Carvana committed securities law violations and may file an action to recover losses for affected investors [4]. - Investors who purchased Carvana common stock and experienced a decline in share value may be eligible to participate in the investigation, regardless of whether they sold their shares [3]. - The firm encourages investors who have lost money to contact them for more information on potential recovery options [5]. Group 3: Whistleblower Information - Individuals with non-public information about Carvana are encouraged to assist in the investigation or report to the SEC under the whistleblower program, which offers rewards of up to 30% of any successful recovery [6]. Group 4: Firm's Reputation and Services - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [7].

Core Viewpoint - Block & Leviton is investigating Travere Therapeutics, Inc. for potential securities law violations following a significant drop in its stock price after the FDA extended the review timeline for its drug application [1][2]. Group 1: Company Overview - Travere Therapeutics, Inc. experienced a trading halt after its shares fell over 30% on January 13, 2026, due to the FDA's extension of the review timeline for the supplemental New Drug Application for FILSPARI [2]. - The FDA set a new PDUFA target action date of April 13, 2026, citing that additional responses from Travere constituted a major amendment and required further data to assess clinical benefit [2]. Group 2: Investigation Details - Block & Leviton is examining whether Travere Therapeutics adequately disclosed the risks associated with the review extension and if prior communications regarding the regulatory timeline were misleading [2][4]. - The firm is open to representing investors who have lost money in Travere's stock, regardless of whether they have sold their shares [3][4]. Group 3: Investor Actions - Investors who have incurred losses are encouraged to contact Block & Leviton for potential recovery options [5]. - Whistleblowers with non-public information about Travere Therapeutics are invited to assist in the investigation, with the possibility of receiving rewards from the SEC [6]. Group 4: Firm Credentials - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [7].

Core Viewpoint - Block & Leviton is investigating Wealthfront Corp. for potential securities law violations following significant net deposit outflows and disclosures regarding the CEO's stake in a new business venture [1][2]. Group 1: Company Performance - Wealthfront reported $208 million in net deposit outflows, a stark decline from the previous year's $874 million in inflows [2]. - The company's shares fell more than 15% on January 13, indicating a negative market reaction to the financial disclosures [2]. Group 2: Legal Investigation - Block & Leviton is looking into whether Wealthfront committed securities law violations and may pursue legal action to recover losses for affected investors [4]. - Investors who have lost money on Wealthfront's stock are encouraged to contact Block & Leviton for potential recovery options [3][5]. Group 3: Whistleblower Information - Individuals with non-public information about Wealthfront are invited to assist in the investigation or report to the SEC under the whistleblower program, with potential rewards of up to 30% of any successful recovery [6]. Group 4: Firm's Reputation - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [7].

Group 1 - Aquestive Therapeutics, Inc. is under investigation by Levi & Korsinsky for potential violations of federal securities laws following an FDA letter identifying deficiencies in its NDA application for Anaphylm [1] - On January 9, 2026, the FDA's letter precluded labeling discussions and post-market commitments for Anaphylm, which is intended for the emergency treatment of anaphylaxis [1] - Following this news, Aquestive's stock price dropped by $2.18, a decline of 35.1%, opening at $4.03 [2] Group 2 - Levi & Korsinsky LLP has a strong reputation in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [3] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [3]

Core Viewpoint - The Gross Law Firm is notifying shareholders of SLM Corporation regarding a class action lawsuit due to alleged misleading statements and undisclosed information related to the company's financial stability and loan delinquency rates [1][3]. Group 1: Allegations - The complaint alleges that during the class period from July 25, 2025, to August 14, 2025, SLM Corporation experienced a significant increase in early-stage delinquencies [3]. - It is claimed that SLM overstated the effectiveness of its loss mitigation and loan modification programs, as well as the overall stability of its private education loan delinquency rates [3]. - As a result of these issues, the defendants' public statements created a materially false and misleading impression regarding SLM's business operations and future prospects [3]. Group 2: Class Action Details - Shareholders who purchased SLM shares during the specified class period are encouraged to register for the class action, with a deadline set for February 17, 2026 [4]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates on the case's status [4]. - There is no cost or obligation for shareholders to participate in this case [4]. Group 3: Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit and illegal business practices [5]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [5].

Core Viewpoint - Integer Holdings Corporation is facing a class action lawsuit due to allegations of issuing materially false and misleading statements regarding its competitive position and sales performance in the electrophysiology manufacturing market [3]. Group 1: Allegations - The complaint alleges that Integer overstated its competitive position within the growing electrophysiology manufacturing market [3]. - Despite claims of strong visibility into customer demand, the company was experiencing a sustained deterioration in sales related to two of its electrophysiology devices [3]. - Integer mischaracterized its electrophysiology devices as a long-term growth driver for the cardio & vascular segment [3]. - As a result of these issues, the defendants' positive statements about the company's business, operations, and prospects were materially false and misleading [3]. Group 2: Class Action Details - The class period for the lawsuit is from July 25, 2024, to October 22, 2025 [3]. - Shareholders who purchased shares during this period are encouraged to register for the class action, with a deadline of February 9, 2026, to seek lead plaintiff status [4]. - There is no cost or obligation for shareholders to participate in the case [4].

Core Viewpoint - A class action lawsuit has been filed against Bath & Body Works, Inc. for alleged violations of securities laws, claiming the company made false and misleading statements regarding its performance and strategies [1][2]. Group 1: Lawsuit Details - The class period for the lawsuit is from June 4, 2024, to November 19, 2025, with a deadline for lead plaintiff appointments set for March 16, 2026 [2]. - The complaint alleges that Bath & Body Works' strategy of "adjacencies, collaborations and promotions" did not lead to sales growth or improved customer metrics, and that the company used brand collaborations to obscure its poor performance [2]. Group 2: Investor Participation - Shareholders who purchased shares during the class period are encouraged to contact the law firm for potential lead plaintiff appointments, although such an appointment is not necessary to participate in any recovery [2].

Core Viewpoint - Mereo BioPharma Group plc is under investigation for potential violations of federal securities laws following disappointing clinical trial results that led to a significant drop in stock price [1][2]. Group 1: Company Overview - Mereo BioPharma Group plc announced results from its Phase 3 ORBIT and COSMIC studies for setrusumab (UX143) in Osteogenesis Imperfecta (OI) on December 29, 2025 [2]. - The studies did not achieve their primary efficacy endpoint of reducing the annualized clinical fracture rate compared to placebo [2]. Group 2: Stock Performance - Following the announcement of the clinical trial results, Mereo's stock price plummeted over 89%, opening at $0.25 per share [2]. Group 3: Legal Investigation - Levi & Korsinsky has commenced an investigation into Mereo BioPharma Group plc concerning potential violations of federal securities laws, inviting affected investors to explore recovery options [1][3].

Group 1 - The Gross Law Firm is notifying shareholders of Klarna Group plc regarding a class action lawsuit related to the company's initial public offering (IPO) on September 10, 2025 [1] - Shareholders who purchased Klarna securities during the class period are encouraged to register for potential lead plaintiff appointment, with a deadline set for February 20, 2026 [3] - The lawsuit alleges that Klarna's management materially understated the risk of increased loss reserves shortly after the IPO, leading to misleading public statements [2] Group 2 - The Gross Law Firm aims to protect investors' rights and seeks recovery for those who suffered losses due to misleading statements or omissions by companies [4] - The firm emphasizes its commitment to responsible business practices and good corporate citizenship [4] - Shareholders who register will receive updates through a portfolio monitoring software throughout the case lifecycle [3]